Thyroid hormone receptor and lipid regulation

Current Opinion in Investigational Drugs

Volumn 11, Issue 10, 2010, Pages 1135-1142

  Webb, P ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cholesterol; dyslipidemia; lipid metabolism; lipoprotein; selective modulation; thyroid hormone receptor; triglyceride

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; ATORVASTATIN; CHOLESTEROL; EPROTIROME; EZETIMIBE; KB 141; KB 2115; LIOTHYRONINE; MB 07344; PLACEBO; QRX 43; SIMVASTATIN; SOBETIROME; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; TITRACOL; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOTHYROIDISM; LIPID METABOLISM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPID METABOLISM; LIPID REGULATING AGENTS; LIVER; RECEPTORS, THYROID HORMONE; THYROID GLAND;

EID: 77957577068     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Baxter JD, Webb P: Thyroid hormone mimetics: Potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov (2009) 8(4):308-320.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366(9493):1267-1278.
3. Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet (2008) 371(9607):117-125.
4. Goldstein JL, Brown MS: The LDL receptor. Arterioscler Thromb Vasc Biol (2009) 29(4):431-438.
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association, National Heart, Lung and Blood Institute: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation (2002) 106(8):1024-1028. (Pubitemid 34925341)
6. Yen PM: Physiological and molecular basis of thyroid hormone action. Physiol Rev (2001) 81(3):1097-1142.
7. Cheng SY, Leonard JL, Davis PJ: Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 31(2):139-170.
8. Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 49(1):306-317.
9. Simpkins S: Dintrophenol and desiccated thyroid in the treatment of obesity. J Am Med Assoc (1937) 108:2110-2119.
10. Stamler J: The Coronary Drug Project - Findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol (1977) 82:52-75.
11. Hill SR Jr, Barker SB, McNeil JH, Tingley JO, Hibbett LL: The metabolic effects of the acetic and propionic acid analogs of thyroxine and triiodothyronine. J Clin Invest (1960) 39(3):523-533.
12. Ladenson PW, McCarren M, Morkin E, Edson RG, Shih MC, Warren SR, Barnhill JG, Churby L, Thai H, O'Brien T, Anand I et al: Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: A pilot prospective, randomized, controlled study. J Clin Endocrinol Metab (2010) 95(3):1349-1354.
13. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 14(2):121-141.
14. Visser WE, Friesema EC, Jansen J, Visser TJ: Thyroid hormone transport in and out of cells. Trends Endocrinol Metab (2008) 19(2):50-56.
15. 3-binding protein in cytosol. Trends Endocrinol Metab (2007) 18(7):286-289.
16. Bianco AC, Kim BW: Deiodinases: Implications of the local control of thyroid hormone action. J Clin Invest (2006) 116(10):2571-2579.
17. Ness GC, Pendleton LC, Li YC, Chiang JY: Effect of thyroid hormone on hepatic cholesterol 7a hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun (1990) 172(3):1150-1156.
18. Gullberg H, Rudling M, Forrest D, Angelin B, Vennström B: Thyroid hormone receptor β-deficient mice show complete loss of the normal cholesterol 7α-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol Endocrinol (2000) 14(11):1739-1749.
19. Johansson L, Rudling M, Scanlan TS, Lundåsen T, Webb P, Baxter J, Angelin B, Parini P: Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA (2005) 102(29):10297-10302.
20. Hashimoto K, Yamada M, Matsumoto S, Monden T, Satoh T, Mori M: Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology (2006) 147(9):4292-4302.
21. Lowell BB, Spiegelman BM: Towards a molecular understanding of adaptive thermogenesis. Nature (2000) 404(6778):652-660.
22. Nikkilä EA, Kekki M: Plasma triglyceride metabolism in thyroid disease. J Clin Invest (1972) 51(8):2103-2114.
23. Weiss RE, Refetoff S: Resistance to thyroid hormone. Rev Endocr Metab Disord (2000) 1(1-2):97-108.
24. Forrest D, Vennström B: Functions of thyroid hormone receptors in mice. Thyroid (2000) 10(1):41-52.
25. Scanlan TS: Sobetirome: A case history of bench-to-clinic drug discovery and development. Heart Fail Rev (2010) 15(2): 177-182.
26. Grover GJ, Mellström K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K et al: Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA (2003) 100(17):10067-10072.
27. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL: Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA (2007) 104(39): 15490-15495.
28. Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH: The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology (2000) 141(9):3057-3064.
29. Metabasis Therapeutics Inc: Metabasis Therapeutics announces second quarter 2009 financial results. Press release (2009): August 06.
30. Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B et al: The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA (2008) 105(2):663-667.
31. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B: Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med (2010) 362(10):906-916.
32. Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS: Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: Selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology (2004) 145(4): 1656-1661.
33. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong G, Singh R, Shapses S, Malm J, Webb P et al: Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141. J Steroid Biochem Mol Biol (2008) 111(3-5):262-267.
34. 3) and TRβ agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J (2008) 22(8):2981-2989.
35. Perra A, Kowalik MA, Pibiri M, Ledda-Columbano GM, Columbano A: Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology (2009) 49(4):1287-1296.
36. Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD: Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol (2009) 156(3): 454-465.
37. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, Erion MD: Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology (2009) 49(2):407-417.
38. Clinical portfolio - Soberitome: Quatrx Pharmaceuticals, Ann Arbor, Michigan, MI, USA (2008). www.quatrx.com/clinical/431.htm
39. Metabasis Therapeutics Inc: Metabasis announces promising results from its phase 1b clinical trial for MB07811, its novel product candidate for the treatment of hyperlipidemia. Press release (2008): June 21.
40. Ricote M, Valledor AF, Glass CK: Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: Effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 24(2):230-239.
41. Drover VA, Agellon LB: Regulation of the human cholesterol 7α-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice. Endocrinology (2004) 145(2):574-581.
42. Drover VA, Wong NC, Agellon LB: A distinct thyroid hormone response element mediates repression of the human cholesterol 7α-hydroxylase (CYP7A1) gene promoter. Mol Endocrinol (2002) 16(1):14-23.
43. Gälman C, Bonde Y, Matasconi M, Angelin B, Rudling M: Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology (2008) 134(4):1127-1136.
44. Research & Development - Eprotirome: Karo Bio AB. Novum, Huddinge, Sweden (2009). www.karobio.com/en/Research-Development/Our-RD-Portfolio2/KB2115/
45. Betters JL, Yu L: NPC1L1 and cholesterol transport. FEBS Lett (2010) 584(13):2740-7274.
46. Pullinger CR, Kane JP, Malloy MJ: Primary hypercholesterolemia: Genetic causes and treatment of five monogenic disorders. Expert Rev Cardiovasc Ther (2003) 1(1):107-119.
47. Brunzell JD: Clinical practice. Hypertriglyceridemia. N Engl J Med (2007) 357(10):1009-1017.